A phase II study of clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (Decadron) for newly diagnosed subjects with multiple myeloma

Trial Profile

A phase II study of clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (Decadron) for newly diagnosed subjects with multiple myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BiRD
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 May 2010 to 1 Aug 2022.
    • 29 Dec 2009 Planned end date (1 May 2010) added as reported by ClinicalTrials.gov.
    • 14 Jan 2008 Results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top